Blueprint Medicines Corporation
BPMC
$88.48
-$0.03-0.03%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 86.77% | 76.92% | 62.92% | 50.39% | 9.06% |
| Total Depreciation and Amortization | 39.66% | -19.41% | -19.30% | -7.25% | -0.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -177.41% | -172.17% | -183.68% | -181.70% | 2.39% |
| Change in Net Operating Assets | -57.28% | 23.68% | 14.83% | -126.33% | 23.51% |
| Cash from Operations | 55.91% | 49.48% | 34.03% | 15.66% | 13.03% |
| Capital Expenditure | 71.17% | 34.96% | -41.06% | -40.89% | -80.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -114.78% | -96.17% | -192.23% | 158.35% | 306.30% |
| Cash from Investing | -117.33% | -101.72% | -317.06% | 177.25% | 283.25% |
| Total Debt Issued | 50.08% | 50.00% | 77.74% | -28.92% | -28.92% |
| Total Debt Repaid | -1,129.55% | -- | -- | -- | -- |
| Issuance of Common Stock | 493.73% | 1,508.53% | 1,077.36% | 1,179.11% | 160.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 129.07% | 162.63% | -7.58% | -66.78% | -78.78% |
| Foreign Exchange rate Adjustments | -550.00% | 367.36% | -164.79% | -174.87% | 197.58% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 174.03% | 115.24% | 83.14% | -138.45% | 51.91% |